Shamburg News · 8-K filed Nov 10, 2026, 8:02 AM EST

Co-Diagnostics Reports Third Quarter 2026 Net Loss of $6.3 Million, Revenue of $0.3 Million

CODX · Co-Diagnostics, Inc.

  • Earnings
  • Financing
  • Reg FD disclosure
  • Materiality: high

Co-Diagnostics, Inc. reported unaudited results for the quarter ended September 30, 2026, with total revenue of $282,881 compared with $145,380 a year earlier. The net loss was $6,306,408, or $1.01 per basic and diluted share, versus a net loss of $5,886,823, or $4.66 per share, in the prior-year quarter. After quarter end, the Company completed a senior secured convertible debt financing with J.J. Astor & Co. with approximately $2.1 million in initial funding and up to an additional $1.0 million subject to conditions.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001493152-26-050868.

Written from the filing by Shamburg Markets. Figures are as reported by the company.